[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:braf-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"BRAF Gene",49,42,[8,16,23,29,35,41,47,54,60,66,72,78,85,91,96,102,109,115,122,128,134,140,146,152,158,163,169,175,181,187,193,199,205,211,217,223,228,234,240,246,252,258,264,271,277,284,290,296,302],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06561360","A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)",[12],"Phase 2","RECRUITING","2026-08-26T02:17:35.666428Z","2026-07-05T05:32:16.759375Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07318324","Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer",[20],"Phase 1","2026-08-26T02:17:46.653867Z","2026-07-05T05:32:16.676290Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04302025","A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",[12],"2026-08-26T02:16:08.402952Z","2026-06-16T05:54:07.906610Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04775485","A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors",[12],"2026-08-26T02:18:45.196599Z","2026-05-05T02:43:29.733815Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07110246","Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas",[12],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:29.642380Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT02870244","Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes",[20],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:29.498267Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT03803553","Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer",[51],"Phase 3","2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.200175Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06121180","Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma",[12],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:29.039725Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06745908","Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In",[51],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.120702Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06246916","A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)",[51],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:28.113147Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06482905","Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.",[20],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:28.000760Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":83,"content_modified":84},"NCT06965114","Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia",[82],"Phase 1\u002FPhase 2","2026-08-26T02:15:56.561131Z","2026-05-05T02:43:27.916844Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT01638676","A Phase I\u002FII Trial of Vemurafenib and Metformin to Melanoma Patients",[82],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.855961Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":64,"content_modified":95},"NCT06959550","Phase II Study of Anti-PD-1\u002FVEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer",[12],"2026-05-05T02:43:27.636070Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06264180","VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",[51],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.479001Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":107,"content_modified":108},"NCT04741997","Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma",[106],"Early Phase 1","2026-08-26T02:17:53.433613Z","2026-05-05T02:43:27.319624Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07224425","A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps",[20],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:27.289591Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":120,"content_modified":121},"NCT06697301","Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.",[119],"Phase 2\u002FPhase 3","2026-08-26T02:15:54.846520Z","2026-05-05T02:43:26.952939Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06194929","Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",[82],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.716817Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT04903119","Nilotinib Plus Dabrafenib\u002FTrametinib or Encorafenib\u002FBinimetinib in Metastatic Melanoma",[20],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:26.680355Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06771544","Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma",[12],"2026-08-26T02:17:34.833510Z","2026-04-29T02:57:57.160553Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",[82],"2026-08-26T02:15:39.267524Z","2026-04-29T02:57:57.062678Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT04511013","A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases",[12],"2026-08-26T02:16:55.892527Z","2026-04-29T02:57:57.062056Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT06060613","Safety and Efficacy of OBX-115 in Advanced Solid Tumors",[82],"2026-08-26T02:15:38.131683Z","2026-07-05T05:32:16.743163Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":64,"content_modified":162},"NCT04752826","BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)",[82],"2026-05-05T02:43:28.727191Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT05009992","Combination Therapy for the Treatment of Diffuse Midline Gliomas",[12],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:28.301737Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",[20],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.481677Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT06249048","Phase 1\u002F2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab",[82],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:26.920220Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT05503797","A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",[12],"2026-08-26T02:19:21.761002Z","2026-07-30T01:46:14.464355Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT05512208","A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib",[12],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:29.586102Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT05101070","S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors",[82],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:28.621667Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[20],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT05859074","A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.807952Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT05538130","A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors",[20],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:27.578185Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[82],"2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":197,"content_modified":227},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[20],"2026-07-24T01:27:14.906567Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT06878131","Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease",[],"2026-08-26T02:19:11.399072Z","2026-05-13T02:55:06.589009Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT05024929","Targeted Therapy to Increase RAI Uptake in Metastatic DTC",[],"2026-08-26T02:15:44.309045Z","2026-05-13T02:55:06.280918Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT03042221","Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy",[],"2026-08-26T02:17:27.435233Z","2026-05-13T02:55:06.106741Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT04888936","Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies",[],"2026-08-26T02:17:59.904383Z","2026-05-13T02:55:06.274852Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT04151940","PET\u002FCT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer",[],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.577751Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT02609685","Active Surveillance of Papillary Thyroid Microcarcinoma",[],"2026-08-26T02:17:09.131534Z","2026-05-05T02:35:31.863089Z",{"nct_id":265,"title":266,"phases":267,"status":268,"updated_at":269,"content_modified":270},"NCT06683755","Phase I\u002FIIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)",[82],"NOT_YET_RECRUITING","2026-08-26T02:18:37.277498Z","2026-05-05T02:43:28.495710Z",{"nct_id":272,"title":273,"phases":274,"status":268,"updated_at":275,"content_modified":276},"NCT06943664","Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer",[12],"2026-08-26T02:18:51.833592Z","2026-04-29T02:57:57.162640Z",{"nct_id":278,"title":279,"phases":280,"status":281,"updated_at":282,"content_modified":283},"NCT04324112","Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed\u002FRefractory HCL",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:21:18.692511Z","2026-05-05T02:43:29.644900Z",{"nct_id":285,"title":286,"phases":287,"status":281,"updated_at":288,"content_modified":289},"NCT06074588","Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)",[51],"2026-08-03T02:08:28.425355Z","2026-05-05T02:35:31.905794Z",{"nct_id":291,"title":292,"phases":293,"status":281,"updated_at":294,"content_modified":295},"NCT04291105","Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients",[12],"2026-08-03T02:31:37.197247Z","2026-05-05T02:43:28.820519Z",{"nct_id":297,"title":298,"phases":299,"status":281,"updated_at":300,"content_modified":301},"NCT05554328","Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial",[12],"2026-08-03T03:36:04.680662Z","2026-05-05T02:43:27.963217Z",{"nct_id":303,"title":304,"phases":305,"status":281,"updated_at":307,"content_modified":308},"NCT03975829","Pediatric Long-Term Follow-up and Rollover Study",[306],"Phase 4","2026-08-03T01:58:01.892442Z","2026-05-13T02:55:06.182080Z"]